Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

47%

7 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2

4(28.6%)

Phase 3

4(28.6%)

N/A

3(21.4%)

Phase 4

3(21.4%)

14Total

Phase 2(4)

Phase 3(4)

N/A(3)

Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT06974526Phase 2Recruiting

Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction

Role: lead

NCT05570786Phase 2Completed

Subdermal Implant-bioabsorbable Gestrinone Pellet for Endometriosis Pelvic Pain Treatment

Role: lead

NCT06136208Not ApplicableCompleted

Pharmacokinetic Aspects of 25-mg Estradiol Pellet in Climacteric Women

Role: lead

NCT07005648Not Yet Recruiting

Brazilian Registry of Menopausal Health

Role: lead

NCT06980961Not ApplicableRecruiting

Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis

Role: lead

NCT06962813Not ApplicableCompleted

Transdermal Radiofrequency V ERASER Versus Polidocanol Sclerotherapy for Reticular Veins and Telangiectasias

Role: lead

NCT06958588Phase 4Recruiting

Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis

Role: lead

NCT06873321Phase 4Recruiting

VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

Role: lead

NCT04853719Phase 4Completed

Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

Role: lead

NCT05102396Phase 2Recruiting

Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?

Role: collaborator

NCT05077930Phase 2Completed

Convalescent Plasma Therapy for Hospitalized Patients With COVID-19

Role: collaborator

NCT04724629Phase 3Completed

Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

Role: collaborator

NCT04662684Phase 3Completed

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial

Role: lead

NCT04999176Phase 3Unknown

Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin

Role: collaborator

NCT04229264Phase 3Unknown

Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

Role: lead

All 15 trials loaded